EP3247709B1 - Calixpyrrolverbindungen und kreatininselektive elektroden damit - Google Patents

Calixpyrrolverbindungen und kreatininselektive elektroden damit Download PDF

Info

Publication number
EP3247709B1
EP3247709B1 EP15750267.5A EP15750267A EP3247709B1 EP 3247709 B1 EP3247709 B1 EP 3247709B1 EP 15750267 A EP15750267 A EP 15750267A EP 3247709 B1 EP3247709 B1 EP 3247709B1
Authority
EP
European Patent Office
Prior art keywords
compound
alkyl
formula
group
creatinine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP15750267.5A
Other languages
English (en)
French (fr)
Other versions
EP3247709C0 (de
EP3247709A1 (de
Inventor
Louis Adriaenssens
Pau BALLESTER
Francisco Javier ANDRADE
Pascal BLONDEAU
Francesc Xavier RIUS
Tomás De Aquino GUINOVART PAVÓN
Daniel HERNÁNDEZ ALONSO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Catala dInvestigacio Quimica ICIQ
Institucio Catalana de Recerca i Estudis Avancats ICREA
Universitat Rovira i Virgili URV
Original Assignee
Institut Catala dInvestigacio Quimica ICIQ
Institucio Catalana de Recerca i Estudis Avancats ICREA
Universitat Rovira i Virgili URV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Catala dInvestigacio Quimica ICIQ, Institucio Catalana de Recerca i Estudis Avancats ICREA, Universitat Rovira i Virgili URV filed Critical Institut Catala dInvestigacio Quimica ICIQ
Publication of EP3247709A1 publication Critical patent/EP3247709A1/de
Application granted granted Critical
Publication of EP3247709B1 publication Critical patent/EP3247709B1/de
Publication of EP3247709C0 publication Critical patent/EP3247709C0/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/16—Organic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
    • C08J5/20—Manufacture of shaped structures of ion-exchange resins
    • C08J5/22—Films, membranes or diaphragms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/16—Nitrogen-containing compounds
    • C08K5/32—Compounds containing nitrogen bound to oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/49—Phosphorus-containing compounds
    • C08K5/51—Phosphorus bound to oxygen
    • C08K5/53—Phosphorus bound to oxygen bound to oxygen and to carbon only
    • C08K5/5317—Phosphonic compounds, e.g. R—P(:O)(OR')2
    • C08K5/5333—Esters of phosphonic acids
    • C08K5/5373—Esters of phosphonic acids containing heterocyclic rings not representing cyclic esters of phosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/55—Boron-containing compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/28—Electrolytic cell components
    • G01N27/40—Semi-permeable membranes or partitions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2327/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Derivatives of such polymers
    • C08J2327/02—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Derivatives of such polymers not modified by chemical after-treatment
    • C08J2327/04—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Derivatives of such polymers not modified by chemical after-treatment containing chlorine atoms
    • C08J2327/06—Homopolymers or copolymers of vinyl chloride

Definitions

  • the present invention relates to the fields of analytical chemistry and medicine.
  • the present invention refers to calixpyrrole compounds useful as creatinine selective ionophores, to membranes, electrodes, and devices including them as well as to methods for determining the amount of creatinine in a test sample using them.
  • Creatinine is a normal metabolic by-product generated by the cells. Since its accumulation is toxic, creatinine is transported by the bloodstream to the kidneys to be filtered out and excreted through the urine. For this reason, the levels of creatinine in blood or urine are key parameters used to evaluate proper kidney function. Creatinine levels are used to calculate the glomerular filtration rate (GFR), a magnitude used to assess the performance of the kidneys. The normal levels of creatinine in blood, which depend on age and sex, are well established. High levels of creatinine reflect a disease or a condition affecting the kidneys -such as infections, illnesses, chronic failures, etc.- that may lead from mild to severe health risks, and even death.
  • GFR glomerular filtration rate
  • creatinine levels must be carefully and frequently checked, since they are used to determine when the haemodialysis treatment must be performed. Creatinine clearance is also required before many medical treatments, such as chemotherapy. Additionally, in urine analysis, creatinine is used as normalization factor to minimize the variability due to volume dilution.
  • the literature deals with many more examples where the determination of creatinine in biological fluids and clinical samples is important. All in all, the precise determination of the levels of creatinine in biological fluids, particularly blood and urine, is extremely relevant. For this reason, it is one of the most commonly required determinations in the routine of the clinical laboratories.
  • colorimetric methods are not free from interferences. From one side, the response depends strongly on the colour of the sample. Turbidity or highly coloured samples may lead to significant errors. Other molecules that can affect the development of the colour may also act as chemical interferences. For example, it has been demonstrated that substances such as acetone, cefazolin, cefoxitin, ceftiofur and glucose can lead to positive biased results, while acetoacetic acid, bilirubin and lipids can yield a negatively biased values in serum measurements (Jacobs, R. M. et al., 1991). Therefore, although universally used, colorimetric methods are not free of analytical and practical problems.
  • ID-GC-MS isotope dilution gas chromatography-mass spectrometry
  • amperometric biosensors are the most common electrochemical methods so far. These biosensors mainly rely on a three-enzyme method, which involves a three-stage conversion of creatinine to creatine, creatine to sarcosine and sarcosine to glycine. At the end, the generation of H 2 O 2 produced during the last stage is monitored. This type of approach is common to amperometric systems. Immobilization of these enzymes has been studied for decades, and a portable clinical analyzer called iSTAT ® is already in the market where the enzymes are immobilized on cartridges that are commercially available.
  • Galán A. et al. discloses the calix[4]pyrrole: where R 9 is C 12 H 23 .
  • the present inventors have developed new calixpyrrole compounds which are useful as creatinine ionophores. As shown below, when a calixpyrrole such as those disclosed herein is used as ionophore in the manufacture of a sensor, it is found that the resulting sensor shows high selectivity for creatinine in front of other ions (interferences) present in real samples. Therefore, the use of this novel ionophores minimizes the drawbacks produced by typical interferences, such as K + .
  • FIG. 1 is illustrative of the fact that the compounds of the invention provide good sensitivity, since they allow the detection of the analyte at very low concentrations.
  • the findings provided by the present inventors means a great advance in the field of clinical analysis because it is the first time that an ionophore can be formulated in a membrane for the potentiometric detection of creatinine in a real sample, the membrane meeting the analytical performance, such as limit of detection, stability, selectivity coefficients, among others (see Table 3 below) required for the determination of creatinine in real samples.
  • the compounds of the present invention confer to sensors the selectivity and usability in potentiometric methods means a great advance in the clinical analysis because (a) the determination is performed in a fast and simple way since no special treatment of the sample is required prior to the determination and no special reagents (such as enzymes) are necessary in the detection; (b) the required volume of sample is very low; (c) the materials needed for the potentiometric method are cheap (the support of the membrane can be a paper sheet for instance); (d) as not being required the use of enzymes, it is stable so it can be stored for long periods of time.
  • the present invention provides a compound of formula (Ia), or alternatively (Ib) or alternatively (Ic), or any of the stereoisomers of (Ia), (Ib) or (Ic)
  • the selectivity for creatinine is due to the common calixpyrrole structure having at least one bridge formed by members -Y-Z-Y-, this bridge forming a ring connecting the two non-adjacent carbon atoms to which R 1 radicals are attached.
  • the compounds of formula (Ia), (Ib), or (Ic), or a stereoisomer thereof of the present invention can be incorporated into a suitable membrane which, as shown in the experimental data, is selective to creatininium ions.
  • a membrane comprising: (i) a compound of formula (Ia), (Ib), or (Ic), or a compound of formula (IV), (V), or a stereoisomer thereof, as defined above or a compound of formula (VI), (ii) a polymeric matrix; (iii) a plasticizer; and (iv) a cation-exchanger salt.
  • a second aspect of the invention refers to the use in vitro as a creatinine selective electrode of the membrane as defined herein.
  • the suitable combination of all these elements (i) to (iv) produces an ion-selective membrane for the detection of creatinine which, by proper adjustment of the pH of the sample, allows the fast, selective and sensitive determination of creatinine in real samples such as urine and plasma.
  • the sensor exhibits an almost Nernstian response (54.2 ⁇ 0.6 mV/log aCreatinine), a linear range from 10 -6 M to 10 -2 M of creatinine, and limits of detection typically in the range of 10 -6.2 M of creatinine
  • a third aspect of the invention refers to the use, in vitro, as a creatinine selective electrode of the electrode comprising the membrane as herein defined.
  • the compounds of the present invention show a short response time (when the addition of a creatinine solution was added to the medium, the electrode lasted about 10 seconds in giving the new measure of potential) and good stability because the potential signal is kept continue and constant until the addition of a new solution of creatinine at a different concentration.
  • FIG. 2 it can be concluded that when a sensor comprising a compound of the invention is used, there is a Nernstian response, which means that there is a linear relationship between the creatinine concentration and the signal and that, therefore, the sensor works adequately.
  • FIG. 1 the compounds of the present invention show a short response time (when the addition of a creatinine solution was added to the medium, the electrode lasted about 10 seconds in giving the new measure of potential) and good stability because the potential signal is kept continue and constant until the addition of a new solution of creatinine at a different concentration.
  • the senor is able of detecting concentrations of the order of 10 -6 , whereas the same membrane without such compound does not. From FIG. 2 it can also be concluded, therefore, that the inclusion of a compound of the invention confers to the sensor an appropriate sensitivity to creatinine.
  • the inclusion of a compound of the invention in a sensor allows the simple and fast determination of creatinine in clinical samples, such as plasma and urine, with minimal sample manipulation.
  • a fourth aspect of the invention refers to the use, in vitro, as a creatinine selective electrode of the device comprising the electrode as herein defined.
  • the compounds of the present invention allow the specific detection of creatinine ions in a test sample. Consequently, these compounds are useful in the routine determination of creatinine levels in any test sample.
  • the present invention provides a method for the quantification of a creatinine in an isolated test sample comprising the step of (a) contacting the test sample with a membrane, electrode or device as defined in any of the previous aspects; and (b) correlating the potential value with the amount of creatinine comprised in the sample.
  • the compounds of the invention are highly selective for creatinine, so when they are formulated in membrane and are placed in contact with the test sample, they selectively "trap" creatinine at the interface between the solution and the membrane.
  • the experimental data provided below supports the fact that the sensor is selective for creatinine, even at low concentrations. This is indicative that the compounds of the invention are receptors specific for creatinine. This is indicative of the usability of the compounds of the invention as ionophore.
  • the invention provides the use of a compound of formula (Ia), (Ib), or (Ic) as defined above thereof as ionophore.
  • the invention provides the use in vitro a compound of formula (Ia), (Ib), or (Ic) or of a compound of formula (IV), (V), or a stereoisomer thereof or a compound of formula (VI) as ionophore specific for creatinine.
  • creatinine is widely used as biomarker of several disorders. Since the compounds of the present invention show high selectivity for creatinine, they can be useful, either alone or formulated in the form of a membrane, electrode, or device, as a diagnostic/prognostic tool in creatinine-disease related disorders.
  • the present invention provides the use, in vitro, as a creatinine selective electrode, of a compound of formula (Ia), (Ib), or (Ic) as defined above, or of a compound of formula (IV), (V), or a stereoisomer thereof or a compound of formula (VI) for use in diagnostics or prognosis.
  • the oxygen radical can be inside the structure (thus being R 4 outside), or oxygen can be outside the structure (thus being R 4 inside).
  • the present invention provides new compounds of formula (Ia), (Ib), or (Ic) useful as creatinine ionophores.
  • alkyl refers to a linear or branched hydrocarbon chain which contains the number of carbon atoms specified in the description or the claims. Examples include, among others, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, octyl, heptyl, nonanyl, decanyl, undecanyl, dodecanyl, and tert-butyl.
  • alkenyl refers to a branched or linear alkyl chain which contains the number of carbon atoms specified in the description or claims and that also contains one or two double bonds. Examples include, among others, ethenyl, 1-propen-1-yl, 1-propen-2-yl, 3-propen-1-yl, 1-buten-1-yl, 1-buten-2-yl, 3-buten-1-yl, 3-buten-2-yl, 2-buten-1-yl, 2-buten-2-yl, 2-methyl-1-propen-1-yl, 2-methyl-2-propen-1-yl, 1,3-butadien-1-yl, 1,3-butadien-2-yl, and dodecenyl.
  • alkynyl refers to refers to a branched or linear alkyl chain which contains the number of carbon atoms specified in the description or claims and that also contains one or two triple bonds.
  • haloalkyl refers to a linear or branched hydrocarbon chain which contains the number of carbon atoms specified in the description or the claims, wherein at least one of the hydrogen atoms is replaced by an halogen atom selected from F, Cl, I, and Br.
  • a ring system formed by "isolated” rings means that the ring system is formed by two, three or four rings and said rings are bound via a bond from the atom of one ring to the atom of the other ring.
  • isolated also embraces the embodiment in which the ring system has only one ring.
  • Illustrative non-limitative examples of known ring systems consisting of one ring are those derived from: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, phenyl, biphenylyl, and cycloheptenyl.
  • the ring system when the ring system has "totally fused" rings, it means that the ring system is formed by two, three or four rings in which two or more atoms are common to two adjoining rings.
  • Illustrative non-limitative examples are 1,2,3,4-tetrahydronaphthyl, 1-naphthyl, 2-naphthyl, anthryl, or phenanthryl.
  • the ring system when the ring system is "partially fused", it means that the ring system is formed by three or four rings, being at least two of said rings totally fused (i.e. two or more atoms being common to the two adjoining rings) and the remaining ring(s) being bound via a bond from the atom of one ring to the atom of one of the fused rings.
  • Y 1 to Y 4 are selected from the group consisting of: (C 6 -C 20 )aryl; and (C 6 -C 20 )aryl substituted with one or more radicals independently selected from the group consisting of: (C 1 -C 20 )alkyl, (C 1 -C 6 )alkyl-O-, (C 1 -C 6 )haloalkyl, halogen, cyano, and nitro.
  • Y 1 to Y 4 are C 6 -C 20 aryl.
  • Y 1 to Y 4 are phenyl.
  • FG 1 and FG 2 are in meta position.
  • radicals FG 1 and FG 2 are -OH and are in meta position.
  • Z 1 to Z 4 radicals are diradicals of formula (III) as defined above, wherein A 1 and A 2 are the same.
  • Z 1 to Z 4 radicals are diradicals of formula (III) as defined above wherein A 1 and A 2 are -O- diradicals.
  • R 6 and R 7 are the same.
  • R 6 and R 7 are hydrogen.
  • R 4 is selected from the group consisting of: (C 1 -C 20 )alkyl, (C 6 -C 20 )aryl, and (C 6 -C 20 )aryl substituted as defined above. In another embodiment, R 4 is (C 6 -C 20 )aryl, and (C 6 -C 20 )aryl substituted as defined above. In another embodiment R 4 is a (C 6 -C 20 )aryl radical.
  • R 4 is selected from the group consisting of: phenyl, tolyl, mesitylenyl, naphthyl, bipheynylyl, quinolinyl N-oxide, quinolinyl N-sulfide and anthracenyl. In another embodiment R 4 is a phenyl radical.
  • R 5 is selected from the group consisting of: (C 1 -C 20 )alkyl, (C 6 -C 20 )aryl, and (C 6 -C 20 )aryl substituted as defined above.
  • R 5 is (C 6 -C 20 )aryl, and (C 6 -C 20 )aryl substituted as defined above.
  • R 5 is a (C 6 -C 20 )aryl radical.
  • R 5 is selected from the group consisting of: phenyl, tolyl, mesitylenyl, naphthyl, bipheynylyl, quinolinyl N-oxide, quinolinyl N-sulfide and anthracenyl. In another embodiment R 5 is a phenyl radical.
  • G is a (C 1 -C 20 )alkyl.
  • G is selected from the group consisting of: methylene, ethylene, propylene, and butylene.
  • G is methylene diradical.
  • Z 1 to Z 4 are -O-CH 2 -O-.
  • Z 1 to Z 4 are -O-CH 2 -O-.
  • R 2 and R 2 are independently selected from the group consisting of H, (C 1 -C 20 )alkyl, (C 1 -C 6 )alkyl-O-, and halogen. In another embodiment R 2 and R 2 are the same. In another embodiment R 2 and R 2 are H.
  • R 1 is selected from the group consisting of: (C 1 -C 20 )alkyl, (C 3 -C 20 )alkenyl, (C 3 -C 20 )alkynyl, and (C 1 -C 20 )haloalkyl.
  • the alkenyl and alkynyl have the double and triple bond, respectively, at the end of the carbon chain.
  • R 1 is (C 1 -C 20 )alkyl.
  • R 1 is selected from the group consisting of: methyl, ethyl, propyl, and butyl.
  • R 1 is methyl.
  • R 1 is dodecanyl.
  • R 1 is dodecenyl.
  • the compound of formula (Ia), (Ib), or (Ic) is selected from the group consisting of: and a stereoisomer thereof; wherein in the compound of formula (Ia6) and (Ib6): X means O or S; and Ar means tolyl, mesitylenyl, naphthyl, bipheynylyl, quinolinyl N-oxide, quinolinyl N-sulfide and anthracenyl. In another embodiment Ar means mesitylene, naphthalene, and anthracene.
  • the compound is selected from the group consisting of: and a stereoisomer thereof; wherein in the compound of formula (Ia6) and (Ib6): R means a (C 1 -C 6 )alkyl; X means O or S; and Ar means mesitylene, naphthalene, and anthracene.
  • the compound is selected from the group consisting of the compounds of formula: (Ia1), (Ib1), ( (Ib11), (Ib12), (Ib13), (Ic3), (Ic4), and a stereoisomer thereof.
  • the compound is selected from the compound of formula (Ia1), compound of formula (Ib1), compound of formula (Ib13), compound of formula (Ic3), and compound of formula (Ic4).
  • the compound of the first aspect of the invention is one of formula (Ia).
  • the compound of formula (Ia) is one wherein Z 1 is a diradical of formula (II) as defined above, wherein A 1 and A 2 are the same. In another embodiment A 1 and A 2 are -O- diradicals.
  • R 4 is selected from the group consisting of: (C 1 -C 20 )alkyl, (C 6 -C 20 )aryl, and (C 6 -C 20 )aryl substituted as defined above.
  • R 4 is selected from (C 6 -C 20 )aryl, and (C 6 -C 20 )aryl substituted as defined above.
  • R 4 is a (C 6 -C 20 )aryl radical.
  • R 4 is selected from the group consisting of: phenyl, tolyl, mesitylenyl, naphthyl, bipheynylyl, quinolinyl N-oxide, quinolinyl N-sulfide and anthracenyl.
  • R 4 is a phenyl radical.
  • the compound of formula (Ia) is one wherein G is a (C 1 -C 20 )alkyl.
  • G is selected from the group consisting of: methylene, ethylene, propylene, and butylene.
  • G is a methylene diradical.
  • R 6 and R 7 are the same.
  • R 6 and R 7 are hydrogen.
  • Y 1 to Y 4 are the same and are selected from the group consisting of: (C 6 -C 20 )aryl; and (C 6 -C 20 )aryl substituted with one or more radicals independently selected from the group consisting of: (C 1 -C 20 )alkyl, (C 1 -C 6 )alkyl-O-, (C 1 -C 6 )haloalkyl, halogen, cyano, and nitro.
  • Y 1 to Y 4 are (C 6 -C 20 )aryl.
  • Y 1 to Y 4 are phenyl.
  • radicals FG 1 and FG 2 are -OH. In another embodiment of the compound of formula (Ia) FG 1 and FG 2 are in meta position. In another embodiment of the compound of formula (Ia) radicals FG 1 and FG 2 are -OH and are in meta position. In another embodiment of the compound of formula (Ia) R 2 and R 2 ' are hydrogen. In another embodiment of the compound of formula (Ia) R 1 is (C 1 -C 20 )alkyl. In another embodiment of the compound of formula (Ia) R 1 is selected from methyl, ethyl, propyl, isopropyl, and tert-butyl. In another embodiment of the compound of formula (Ia) R 1 is methyl.
  • a 1 and A 2 are -O- diradicals;
  • R 4 is a (C 6 -C 20 )aryl radical;
  • Y 1 to Y 4 are the same and are (C 6 -C 20 )aryl;
  • FG 1 and FG 2 are -OH and are in meta position;
  • R 2 and R 2 ' are hydrogen; and R 1 is (C 1 -C 20 )alkyl.
  • the compound of formula (Ia) is selected from the compounds of formula (Ia1), (Ia2), (Ia3), (la4), and (Ia5) and a stereoisomer thereof.
  • the compound of formula (Ia) is the compound of formula (Ia1), and a stereoisomer thereof.
  • the compound of the first aspect of the invention is one of formula (Ib).
  • Z 1 and Z 3 are the same.
  • R 4 is selected from the group consisting of: (C 1 -C 20 )alkyl, (C 6 -C 20 )aryl, and (C 6 -C 20 )aryl substituted as defined above.
  • R 4 is selected from (C 6 -C 20 )aryl, and (C 6 -C 20 )aryl substituted as defined above.
  • R 4 is a (C 6 -C 20 )aryl radical.
  • R 4 is selected from the group consisting of: phenyl, tolyl, mesitylenyl, naphthyl, bipheynylyl, quinolinyl N-oxide, quinolinyl N-sulfide and anthracenyl.
  • R 4 is a phenyl radical.
  • Z 1 and Z 3 are -O-CH 2 -O-.
  • the other Z diradical is -O-(C 1 -C 6 )alkyl-O-
  • R 4 is selected from the group consisting of: (C 1 -C 20 )alkyl, (C 6 -C 20 )aryl, and (C 6 -C 20 )aryl substituted as defined above.
  • R 4 is selected from (C 6 -C 20 )aryl, and (C 6 -C 20 )aryl substituted as defined above.
  • the other Z diradical is -O-(C 1 -C 6 )alkyl-O-
  • R 4 is a (C 6 -C 20 )aryl radical.
  • the other Z diradical is -O-(C 1 -C 6 )alkyl-O-
  • R 4 is selected from the group consisting of: phenyl, tolyl, mesitylenyl, naphthyl, bipheynylyl, quinolinyl N-oxide, quinolinyl N-sulfide and anthracenyl.
  • Y 1 to Y 4 are the same and are selected from the group consisting of: (C 6 -C 20 )aryl; and (C 6 -C 20 )aryl substituted with one or more radicals independently selected from the group consisting of: (C 1 -C 20 )alkyl, (C 1 -C 6 )alkyl-O-, (C 1 -C 6 )haloalkyl, halogen, cyano, and nitro.
  • Y 1 to Y 4 are (C 6 -C 20 )aryl.
  • Y 1 to Y 4 are phenyl.
  • R 2 and R 2 ' are hydrogen.
  • R 1 is selected from methyl, ethyl, propyl, and butyl.
  • R 1 is methyl.
  • the compound of formula (Ib) is selected from the compounds of formula (Ib1), (Ib2), (Ib3), (Ib4), (Ib5), (Ib10) and a stereoisomer thereof.
  • the compound of formula (Ib) is selected from the compounds of formula (Ib1), (Ib7), (Ib8), (Ib9), (Ib10), (Ib11), (Ib12), (Ib13) and a stereoisomer thereof.
  • the compound of formula (Ib) is selected from the compounds of formula (Ib1), (Ib7), (Ib8), (Ib9), (Ib10) and a stereoisomer thereof.
  • the compound of formula (Ib) is selected from the compounds of formula (Ib1), (Ib2), (Ib3), (Ib4), (Ib5), (Ib6), (Ib7), (Ib8), (Ib9), (Ib10) and a stereoisomer thereof.
  • R 1 is methyl.
  • the compound of formula (Ib) is one selected from the compounds of formula (Ib11), (Ib12), (Ib13), and a stereoisomer thereof.
  • the compound of formula (Ib) is selected from a compound of formula (Ib1), (Ib11), (Ib12), (Ib13), and a stereoisomer thereof.
  • the compound is one of formula (Ic).
  • At least one of Z 1 to Z 4 is different from the others.
  • Z 2 , Z 3 , and Z 4 are the same.
  • the other Z diradicals are -O-(C 1 -C 6 )alkyl-O-
  • R 4 is a (C 6 -C 20 )aryl radical.
  • the other Z diradicals are -O-(C 1 -C 6 )alkyl-O-
  • R 4 is selected from the group consisting of: phenyl, tolyl, mesitylenyl, naphthyl, bipheynylyl, quinolinyl N-oxide, quinolinyl N-sulfide and anthracenyl.
  • Y 1 to Y 4 are the same.
  • Y 1 to Y 4 are the same and are selected from the group consisting of: (C 6 -C 20 )aryl; and (C 6 -C 20 )aryl substituted with one or more radicals independently selected from the group consisting of: (C 1 -C 20 )alkyl, (C 1 -C 6 )alkyl-O-, (C 1 -C 6 )haloalkyl, halogen, cyano, and nitro.
  • Y 1 to Y 4 are (C 6 -C 20 )aryl radicals as defined above.
  • Y 1 to Y 4 are phenyl radicals.
  • R 2 and R 2 ' are hydrogen.
  • R 1 is (C 1 -C 20 )alkyl.
  • R 1 is selected from methyl, ethyl, propyl, dodecanyl, and isobutyl.
  • R 1 is methyl.
  • R 1 is dodecanyl.
  • R 1 is (C 3 -C 20 )alkenyl.
  • R 1 is dodecenyl.
  • the compound of formula (Ic) is selected from (Ic1), (Ic2), (Ic3), (Ic4), and a stereoisomer thereof.
  • the compound of formula (Ic) corresponds to the compound of formula (Ic1), (Ic3), (Ic4) or a stereoisomer thereof.
  • the compound of formula (Ic) is selected from (Ic1), and (Ic2).
  • the compound of formula (Ic) is selected from (Ic3), and (Ic4).
  • the present disclosure provides a process for the preparation of the compound of the present invention, as defined above.
  • the process of the present invention comprises the reaction between a compound of formula (VIIa): and a compound of formula (VIII) as defined above.
  • the process comprises the reaction between the compound of formula (VIIa) and a compound of formula (VIII), wherein G is methyl, and B 1 and B 2 are halogen.
  • the compound of formula (VIII) is selected from phenylphosphonic dichloride and bromochloromethane.
  • the process of the present invention comprises the reaction between a compound of formula (VIIa) and a compound of formula (VIII), as defined above.
  • the process comprises the reaction between the compound of formula (VIIa) and a compound of formula (VIII), wherein G is methyl, and B 1 and B 2 are halogen.
  • the compound of formula (VIII) is selected from phenylphosphonic dichloride and bromochloromethane.
  • the compound of formula (VIII) is phenylphosphonic dichloride.
  • the compound of formula (Ib11), (Ib12) or (Ib13) can be obtained by a process comprising:
  • the compound of formula (lb1) or (Ib2) can be obtained by a process comprising the reaction between a compound of formula (Ia1) or (Ia3) as defined above, and a compound of formula (VIII) wherein G is -(C 1 -C 6 )alkyl-, and B 1 and B 2 are halogen.
  • the compound (Ib6) can be obtained reacting the compound of formula (Ia6) as defined above with a compound of formula (IX): C I-P (X)Ar-C I (IX) wherein X means O or S; and Ar means tolyl, mesitylenyl, naphthyl, quinolinyl N-oxide, quinolynyl N-sulfide, bipheynylyl, and anthracenyl.
  • the process of the present invention comprises the reaction between a compound of formula (VIIb) wherein R 1 is methyl or dodecanyl: with a compound of formula (VIII) as defined above.
  • the basic medium is selected from the group consisting of a tertiary amine - NR 9 R 10 R 11 , being R 9 , R 10 , and R 11 radicals independently selected and representing (C 1 -C 6 )alkyl; pyridine; alkaline carbonate; and alkaline (C 1 -C 6 )alkyl-O-.
  • the basic medium is a tertiary amine or an alkaline carbonate.
  • the basic medium is selected from the group consisting of triethylamine and diisopropylethylamine.
  • the basic medium is potassium carbonate.
  • the molar ratio between the basic medium required in the preparation of a compound of formula (Ia), (Ib), or (Ic) and the compound of formula (VIII) is comprised from 2:1 to 15:1.
  • molar ratio between two products refers to the relation of moles of one product vs. the moles of the other product.
  • weight ratio between two products refers to the relation of weight of one product vs. the weight of the other product, both weights being expressed in the same units. In the case of the weight ratio between the plasticizer and the compound of the invention, this means the relation of weight of plasticizer vs the weight of compound of the invention, both expressed in mg.
  • a membrane comprising a compound selected from the compounds of formula (Ia), (Ib), (Ic), (IV), (V) and a stereoisomer thereof, or alternatively the compound is one of formula (VI), together with a plasticizer, a cation-exchanger salt, and a polymeric matrix.
  • the polymeric matrix comprises a polymer or mixture of polymers of high molecular average weight, typically comprised from 70000 to 250000. With such a molecular weight it is guaranteed the inert character of the polymer, independently of its chemical composition.
  • the polymer(s) composing the polymeric matrix has a molecular average weight comprised from 70000 to 250000. In another embodiment the polymer(s) has a molecular average weight comprised from 100000 to 200000.
  • the polymer or mixture of polymers is able of forming thin films.
  • polymers are polyvinyl chloride (also carboxylated), poly(vinylidene chloride), polyvinyl chloride/polyvinyl alcohol, Urushi (Japanese lacquer) acrylate, polysiloxane, siloxane sol-gel and monolayer, poly(acrylonitrile), polyurethanes (particularly aromatic), poly(vinyl butyral), poly(vinyl formal), poly(vinyl acetate), silicone elastomers, cellulose esters and polycarbonates.
  • the polymeric matrix comprises a mixture of polymers of the same or different chemical nature.
  • the skilled person making use of the general knowledge, can routinely choose, among those available in the state of the art, the appropriate polymer(s) in the appropriate amount(s) depending on the compound selected as ionophore.
  • the term "same chemical nature" when comparing two or more polymers forming the polymeric matrix, has to be understood as polymers with the same functional groups in their backbones but differing in the molecular average weight.
  • An illustrative non-limitative example of a mixture of polymers of the "same nature" would be a mixture of polyurethanes, wherein the common functional group to all polyurethanes is the urethane group.
  • such a polymer in combination with the plasticizer, facilitates ionic mobility across the membrane interface.
  • the % by weight of polymeric matrix is comprised from 20 to 40%. In another embodiment, the % by weight of polymeric matrix is comprised from 25 to 35%. In another embodiment, the % by weight of polymeric matrix is comprised from 28 to 32%.
  • percentage (%) by weight refers to the percentage of each component of the membrane in relation to the total weight of the membrane composition.
  • the polymer is poly(vinyl chloride) (PVC).
  • PVC poly(vinyl chloride)
  • the PVC used has a molecular weight comprised from 70000 to 250000.
  • the polymer is PVC having a molecular weight comprised from 100000 to 200000.
  • the PVC is in a % by weight comprised from 20 to 40%.
  • the % by weight of PVC is comprised from 25 to 35%.
  • the % by weight of PVC is comprised from 28 to 32%.
  • plasticizer has to be understood in the present invention as any of the available plasticizers for the manufacturing of ion-selective membranes.
  • Typical plasticizers are for example (but not restricted to) 2-nitrophenyl octyl ether (o-NPOE), bis(2-ethylhexyl) sebacate (DOS) and chloroparaffin, as well as other chemical structures such as phthalates, adipates suberates, azelates, glutarates, succinates and hexahydrophtalates.
  • o-NPOE 2-nitrophenyl octyl ether
  • DOS bis(2-ethylhexyl) sebacate
  • chloroparaffin as well as other chemical structures such as phthalates, adipates suberates, azelates, glutarates, succinates and hexahydrophtalates.
  • Other non-polymeric discrete organic compounds having low molecular weight (usually of 500 to 20.000 molecular weight)
  • plasticizers The function of the plasticizers is to make the membrane softer and much more resistant to mechanical stress such as poking, bending or stretching, as well as reducing the glass transition temperature and increasing the polarity of the membrane. Plasticizers also enhance the flexibility by facilitating the movement of the polymer macromolecules and thus influence the partitioning of ions.
  • the plasticizer must be miscible with the polymeric matrix in the membrane in order to obtain a homogeneous dispersion. Typical mixtures of plasticizer with the polymeric matrix are in a weight ratio comprised from 1:1 to 4:1 (plasticizer:polymer).
  • the plasticizer is present in the membrane in the amount sufficient to solvate the creatinine receptor, anywhere in a weight ratio vs the amount of ionophore comprised 10:1 to 100:1.
  • the weight ratio between the plasticizer and the ionophore is comprised from 10:1 to 30:1. In one embodiment the weight ratio between the plasticizer and the ionophore is comprised from 15:1 to 25:1. In another embodiment, the plasticizer is in a % by weight comprised from 40 to 80%. In another embodiment, the plasticizer is in a % by weight comprised from 55 to 65%. In one embodiment, the plasticizer is 2-nitrophenyl octyl ether. In another embodiment, the weight ratio plasticizer: polymeric matrix is comprised from 1:1 to 4:1. In another embodiment, the weight ratio plasticizer:polymeric matrix is comprised from 2:1 to 3:1.
  • the plasticizer is 2-nitrophenyl octyl ether, and the weight ratio between the 2-nitrophenyl octyl ether and the polymeric matrix is comprised from 2:1 to 3:1.
  • the plasticizer is 2-nitrophenyl octyl ether, it is in % by weight comprised from 55 to 65%, and the weight ratio between the 2-nitrophenyl octyl ether and the polymeric matrix is comprised from 2:1 to 3:1.
  • the membrane of the sensor also includes a cation-exchanger salt which is also soluble in the polymeric matrix.
  • This salt is typically composed, on one hand, by a large organic molecule which is an anion (negatively charged).
  • the counterion is a small cation, such as alkali metals, among many other possibilities.
  • the role of this salt is to facilitate the entrapment of the target analyte from the ionophore in case it is a neutral macromolecule.
  • the inclusion of this lipophilic ionic salt helps to maintain the permselectivity of the membrane where each cation is complemented by a lipophilic anion from the ion-exchanger.
  • the cation exchanger avoids coextraction of ions with different charges from the sample into the membrane phase in order to accomplish the theoretical Nernstian behaviour from an ion-selective electrode.
  • the presence of cation exchanger is required to obtain a membrane that exchanges ions with the same charge sign (called permselectivity or Donnan exclusion).
  • Illustrative non-limitative examples of cation-exchanger salts useful in the manufacture of ion-selective membranes are: sodium tetrakis-[3,5-bis(1,1,1,3,3,3-hexafluoro-2-methoxy-2-propyl)-phenyl]borate trihydrate (NaHFPB) and potassium tetrakis[3,5-(trifluoromethyl)phenyl]borate (KTFPB).
  • the molar ratio of the compound of formula (Ia), (Ib), (Ic), (IV), (V), or a stereoisomer thereof, or alternatively of a compound of formula (VI) and the ion-exchanger salt is comprised from 10:1 to 10:4.
  • This range of molar ratio guarantees the selectivity of the ionophore for its specific analyte (creatinine) to other species present in real samples.
  • the final molar ratio will depend on the particular ion-exchanger salt and ionophore. As it is illustrated below, when the cation-exchanger salt is KTFPB and the ionophore is the compound (Ib1), the optimal molar ratio was about 10:3.
  • the amount in % by weight of ion-exchanger salt is comprised from 0.1 to 2%. In another embodiment, the amount is about 1%.
  • the creatinine-selective membrane of the invention is prepared by dissolving all components in a suitable organic solvent, such as tetrahydrofuran.
  • a suitable organic solvent such as tetrahydrofuran.
  • This solution containing all the membrane components dissolved can be referred hereinafter as "membrane cocktail" and it is used to form the membrane by suitable evaporation of the solvent.
  • the membrane composition may also include chemical substances, nanomaterials or any type of compound that act as "ion-to-electron" transducer, facilitating the generation and stability of the potentiometric signal, as described in the literature.
  • chemical substances nanomaterials or any type of compound that act as "ion-to-electron" transducer, facilitating the generation and stability of the potentiometric signal, as described in the literature.
  • the need to incorporate these substances, and the way to do it, will be evident for any person with knowledge in the field (Tanji yin and Wei qin, 2013).
  • the different components when preparing a membrane composition of the invention, the different components will be in such amounts that they sum up 100% by weight.
  • Electrodes for the determination of the content of a liquid sample have been described by others. They commonly contain a plastic membrane which has an ion-selective component (ionophore) and a solvent/plasticizer compound in which the ion-selective component can be dissolved.
  • ionophore ion-selective component
  • solvent/plasticizer compound in which the ion-selective component can be dissolved.
  • hydrogen ionophores such as lipophilic derivatives of uncouplers of oxidative phosphorylation and lipophilic tertiary amines have been used.
  • Solid-contact ion-selective electrode solid contact ISE
  • a transducer element is required in order to avoid the formation of capacitive layers that affect the stability of the potentiometric readings.
  • these transducing components are electroactive conjugated polymers (conducting polymers), as well as a variety of nanomaterials, such as three-dimensionally ordered mesoporous (3DOM) carbon and different types of carbon nanotubes (CNTs).
  • a solid contact potentiometric sensor is obtained by casting a suitable volume of the polymeric membrane cocktail onto a conductive substrate which can be a transducer layer previously deposited, or alternatively, incorporated into the membrane cocktail. Next, the solvent is evaporated, in order to form a suitable membrane. Alternatively, the solid transducer element can be incorporated with the ion-selective membrane cocktail.
  • Other methods of membrane deposition include dip coating, where the substrate with the transducing layer is submerged into the ion-selective membrane cocktail; spin coating, where the conductor is spun and immersed into the ion-selective membrane cocktail and removed to let it dry.
  • the electrode is submerged into a conditioning solution until stable readings of potential are obtained.
  • Inner-solution ion-selective electrode Inner solution ISE
  • the polymeric membrane is cast onto a glass-casting plate. Once dried, the membrane is gently peeled off and placed in the membrane packing piece of the electrode and finally pressed with the membrane housing to put the membrane in contact with the inner electrolyte solution, which is 10 mM of creatinine in 10 mM buffer solution, the buffer solution providing a pH which is below the creatinine pKa value. Finally, the polymeric membrane is placed in contact with a conditioning solution until stable potential readings are obtained.
  • the buffer for conditioning can be any able to control the pH at values in the range from approximately 3 to approximately 4.5.
  • Buffer solutions can be (but are not restricted to) acetic acid/ acetate, phosphate/citrate, etc., adjusted to the suitable pH value.
  • the conditioning of the creatinine membrane once completely dried consists of immersing the membrane in a buffer solution for such a period of time that allows obtaining stable potential readings along with a creatinine concentration equal or higher than 1 mM.
  • a creatinine concentration equal or higher than 1 mM.
  • the calibration of the electrode is carried out with a buffer solution whose concentration is equal or higher than 10 mM with increasing concentration of creatinine by adding known amounts of creatinine standards.
  • the maximum concentration raised could be about 0.1 M.
  • the device (or potentiometric cell) consists of two electrodes: a reference electrode that keeps a stable and constant potential during the measurements, and the working electrode, in this case the ion-selective electrode, which in this case includes the creatinine selective membrane.
  • the reference electrode can be any type of commercial or homemade system, such as (but not restricted to) silver-silver chloride electrode (in its multiple forms), calomel electrode, etc., that keeps a stable and constant potential during the measurements.
  • the reference electrode is a silver-silver chloride electrode.
  • the working electrode can be either the inner solution ISE or the solid contact ISE, or any other configurations containing the polymeric membrane described above.
  • the reference electrode is a double junction Ag/AgCl/KCl 3 M reference electrode containing 1 M LiAcO as electrolyte bridge, type 6.0729.100 (Metrohm AG, Switzerland).
  • the measuring circuit is assembled in order to be able to properly record the electromotive force generated between these electrodes by a voltmeter.
  • Other measurement arrangements using other electrochemical approaches such as for example chronopotentiometry, pulsetrodes, cyclic voltammetry, etc. or any other techniques using these membranes are also possible.
  • This membrane can also be used for building alternative potentiometric methods, such as those using field effect transistors (ISFET)
  • the present invention provides a process for quantifying the creatinine in a test sample.
  • the test sample can be any bodily test sample, such as blood, urine, and serum, among others.
  • the correlation step between the potential value measured and the concentration of creatinine can be performed generating previously a calibration curve. It is well-known for the skilled person in the art how to obtain
  • This powder was purified by column chromatography (silica gel, 1% MeOH in CH 2 Cl 2 to 10% MeOH in CH 2 Cl 2 , Rf of product was 0.25 with 5% MeOH in CH 2 Cl 2 eluent). The fractions containing principally the desired product were collected together and evaporated under vacuum to give a white powder. This material was recrystallized from boiling MeCN (200 mL) to give pure product as small colourless cubes, 1.925 g (35% yield).
  • Methanesulfonic acid (0.24 mL, 10.77 mmol, 3 equiv.) was added dropwise to a solution of pyrrole (0.25 mL, 3.6 mmol, 1 equiv.) in MeOH (6 mL). The mixture was stirred for 5 min and then a solution of dodecyl-(3',5')dihydroxyphenyl ketone (X) (1.1 g, 3.6 mmol, 1 equiv.) in MeOH (18 mL) was added slowly. The reaction was stirred 20 h at RT. The reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (4 ⁇ 50 mL).
  • Triethylamine (0.22 mL, 1.6 mmol, 2.2 equiv.) followed by phenylphosphonic dichloride (0.11 mL, 0.80 mmol, 1.1 equiv.) were added to a solution of starting tetrahydroxy calixpyrrole (VIIa) (536 mg, 0.72 mmol, 1 equiv.) in THF (anhydrous and degassed, 55 mL, 13 mM) stirring at RT under Argon atmosphere. The reaction mixture was stirred at RT for 16 hours during which time a white precipitate was formed in the reaction mixture.
  • VIPa tetrahydroxy calixpyrrole
  • the reaction mixture was cooled, the sealed tube was opened and the mixture was brought to ⁇ pH 2 with 1M HCl(aq).
  • the resultant mixture was extracted with CH 2 Cl 2 (2 ⁇ 10 mL).
  • the combined organic extracts were washed with water, dried over Na 2 SO 4 , and the CH 2 Cl 2 was evaporated to give a light beige powder.
  • This material was suspended in MeCN (1 mL), the mixture was sonicated and the MeCN was decanted. The remaining solid was dried under vacuum to give the pure di-carbon-bridged receptor (Ib10) as a white powder, 32 mg (77% yield).
  • Triethylamine (1.5 mL, 10.75 mmol, 20 equiv.) followed by phenylphosphonic dichloride (0.2 mL, 1.43 mmol, 2.6 equiv.) were added to a solution of starting tetrahydroxy calixpyrrole (VIIa) (406 mg, 0.55 mmol, 1 equiv.) in THF (anhydrous and degassed, 20 mL, 0.027 M) stirring at room temperature under Argon atmosphere. The reaction was stirred at room temperature for 16 hours during which time a white precipitate was formed in the reaction mixture.
  • VIPa tetrahydroxy calixpyrrole
  • reaction mixture was brought to ⁇ pH 2 with 1M HCl(aq) and the resultant mixture was extracted with CH 2 Cl 2 (3 ⁇ 100 mL). The organic extracts were combined, dried over Na 2 SO 4 and evaporated under vacuum to give a white powder.
  • the reaction crude was first purified by column chromatography (SiO 2 ; CH 2 Cl 2 : MeOH 99:1) in order to remove the oligomers/polymers formed during the reaction with 60% overall yield.
  • the fraction containing the three diastereomers was purified by semipreparative HPLC (Spherisorb silica 250 ⁇ 20 mm, 5 ⁇ m; SiO 2 ; CH 2 Cl 2 : MeOH 99:1) to yield each separated isomer Ib9, Ib8 and Ib7 as white solids (Retention times: 4.8 minutes, 6.19 minutes and 9.8 minutes, respectively).
  • the three isomers can be further purified by crystallization from acetonitrile.
  • the starting calix[4]pyrrole (VIIa) (0.4 g, 0.54 mmol) was dissolved in pyridine (42 mL, 52 mmol) (dried over CaH and freshly distilled) under argon atmosphere forming a colorless solution. Then, phenylphosphine dichloride (150 uL, 1.11 mmol) was added and the reaction mixture turned yellow. With time a white precipitate appeared. 1h and 30 minutes after addition of the phosphine, the reaction mixture was heated at 70°C and stirred for additional 30 minutes. After that time, sulfur (55.4 mg, 0.22 mmol) was added and the reaction was left under stirring at the same temperature overnight.
  • the compound (Ib3) can be obtained following the same process as the one for (Ib1) by replacing compound (Ia1) with a compound of formula (Ia4), obtainable by reaction of a compound of formula (VIIa) with dichlorophosphoramide, as described in Example 4.
  • the compound (Ib4) can be obtained following the same process as the one for (Ib1) by replacing compound (Ia1) with a compound of formula (Ia5), obtainable by reaction of a compound of formula (VIIa) with sulfuryl chloride, as described in Example 4.
  • This precipitate was collected by filtration.
  • This material was purified by column chromatography (silica gel, CH 2 Cl 2 ) collecting the fractions containing the compounds that eluted first. These fractions were purified by semipreparative HPLC (Spherisorb silica 250 ⁇ 20 mm, 5 ⁇ m; SiO 2 ; CH 2 Cl 2 : Hexane 60:40; flow rate: 15 mL/min) to yield the desired product as a white solid (Retention time: 5.3 minutes). The product was further purified by recrystallization from acetonitrile to give the pure product 60 mg, (9%).
  • Example 8 bis Synthesis of tetraphosphonate calixpyrroles (Ic3) and (Ic4)
  • the fraction containing the two diastereomers was purified by semipreparative HPLC (Spherisorb silica 250 ⁇ 20 mm, 5 ⁇ m; SiO 2 ; CH 2 Cl 2 : Hexane 60:40; flow rate: 15 mL/min) to yield each separated isomer Ic3 and Ic4 as white solids (Retention times: 4.3 minutes and 5.3 minutes, respectively).
  • the isomers can be further purified by crystallization from acetonitrile.
  • membranes comprising ionophores (Ia1), (Ib7), (Ib8), (Ib9), (Ib10), (Ib11), (Ib12), (Ib13), (Ic3) and (Ic4) were prepared following the same procedure as the one followed for the membrane comprising ionophore (Ib1), but using the amounts (expressed in milligrams) specified in Table 1bis below:
  • the GC surface was polished with alumina of different sizes (25, 1 and 0.03 ⁇ m, Buehler, USA), with an active surface of 7 mm 2 .
  • Solid-contact ion-selective electrode
  • the next step is to drop-cast 50 ⁇ L of the polymeric membrane solution obtained in Example 9, onto the above conductor and let the solvent evaporate for up to 2 hours.
  • the membrane was subjected to a conditioning step by submerging it into a 10 mM acetic acid/acetate buffer solution containing 10 mM creatinine for 1 hour. This conditioning step was suitable in order to obtain stable measurements when calibrating and measuring with creatinine as well as real samples, respectively.
  • Ion-selective electrode with inner filling solution electrode Ion-selective electrode with inner filling solution electrode:
  • ion-selective electrode with inner filling solution 50 ⁇ L of the polymeric membrane obtained in previous Example 9, were drop-casted on a glass-casting plate. The membrane was gently peeled off and placed in the membrane packing piece of the electrode (Electrode Body ISE, 45137 Sigma Aldrich) and finally pressed with the membrane housing to put the membrane in contact with the inner electrolyte solution, which is 10mM of creatinine in 10mM acetic acid/acetate buffer solution. The final step was the calibration step, wherein the polymeric membrane was placed in contact with a 10 mM creatinine solution and a 10 mM acetic acid/ acetate buffer solution to obtain stable potential readings without noise coming from the first contact of the membrane to the solution.
  • Calibration measurements The measurements were carried out with an acetic acid/acetate buffer solution of 10 mM and the concentration of creatinine was increased by adding amounts of creatinine standards.
  • Example 11 Design of a potentiometric cell device
  • the potentiometric cell assembly consists basically in measuring the potential generated between two electrodes: a Ag/AgCl reference electrode (A double junction Ag/AgCl/KCl 3 M reference electrode containing 1 M LiAcO as electrolyte bridge, type 6.0729.100 was employed (Metrohm AG))that maintains a constant potential, due to the presence of a high concentrated KCl electrolyte coupled to a bridge electrolyte and the sample through a liquid junction; and an ion-selective electrode, which included the creatinine selective membrane or the blank membrane.
  • a Ag/AgCl reference electrode A double junction Ag/AgCl/KCl 3 M reference electrode containing 1 M LiAcO as electrolyte bridge, type 6.0729.100 was employed (Metrohm AG)
  • an ion-selective electrode which included the creatinine selective membrane or the blank membrane.
  • This ion-selective electrode can be either any of the polymeric membranes of Example 9 (Tables 1 and 1bis) in contact with an inner filling solution of 10 mM of creatinine with 10 mM buffer solution at in contact with an Ag/AgCl wire, or the polymeric membrane in contact with a glassy carbon rod as a solid-state ion-selective electrode, in direct contact with the sample.
  • the measuring circuit is assembled in order to be able to record the electromotive force generated between these electrodes by a voltmeter, which may explain the presence or absence of the target analyte.
  • Additions of one logarithmic activity unit were added into the potentiometric cell in order to obtain a potentiometric trace of the sensor as well as a calibration curve, where linear regression and performance of the sensor can be tested out.
  • the selectivity of the electrode of the invention was determined measuring the potential value in different solutions prepared as in the example above.
  • the potentiometric cell used was the one with the solid-contact ion-selective electrode as disclosed in Example 10 with ionophore (Ib1).
  • a negative value is indicative of the selectivity of the sensor, and the more negative the value is, the more selective is the electrode. From Table 3 it can be concluded that the sensor comprising the compound Ib1 of the invention is more selective, particularly in terms of the selectivity towards potassium, which is a serious interference commonly found in biological fluids.
  • the "required selectivity coefficient" calculation is based on the known concentration range of the analyte and the interfering ion in the sample (biological fluids, such as urine).
  • C B and C A stand for the concentration of the interfering anion and the analyte, respectively.
  • the creatinine selective polymeric membrane can be used to facilitate daily measurements by physicians, technicians, among others in the laboratories that require rapid, simple and easy-to-use instrumentation to obtain analytical results.
  • the electrode used was the solid type with the ionophore of the invention of formula (Ib1).
  • the sample is collected at any time followed by a 100 fold dilution with a 0.05 M buffer at pH around 3.7. This step ensures the creatinine to be charged. After that, the potential generated can be recorded with the high-input impedance voltmeter. Electrodes must be cleaned in between measurements with abundant distilled water.
  • the sample In the case of plasma and serum, the sample must be also diluted although in this case the dilution is only 10 times since the amount in both samples is 2 times lower.
  • the sample is collected and diluted 1:10 with a pH 3.7 buffer 0.05 M to obtain the charged creatininium ion. As in the previous sample, the potential is therefore recorded with the voltmeter. Longer response times have been observed after several serum/plasma samples measurements.
  • Table 4 Creatinine values obtained from different plasma samples for the standard method (Jaffé) and the potentiometric method developed here. Plasma samples Jaffé Method (mM) Potentiometric method (mM) 1 0.33 0.36 2 0.57 0.62 3 0.31 0.33 4 0.24 0.29
  • the electrode of the invention is a reliable tool in the measurement of creatinine in real samples.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Manufacturing & Machinery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Materials Engineering (AREA)
  • Food Science & Technology (AREA)
  • Electrochemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (15)

  1. Verbindung der Formel (la), oder alternativ (Ib) oder alternativ (Ic), oder eins der Stereoisomere von (la), (Ib) oder (Ic)
    Figure imgb0067
     in welchen
    R1 ein Monoradikal ausgewählt aus der Gruppe bestehend aus Wasserstoff; (C1-C20)Alkyl; (C3-C20)Alkenyl; (C3-C20)Alkinyl; (C1-C6)Alkyl-O-; (C1-C20)Haloalkyl; (C6-C20)Aryl; (C6-C20)Aryl substituiert mit einem oder mehreren Radikalen unabhängig ausgewählt aus (C1-C20)Alkyl, (C1-C6)Alkyl-O-, (C1-C6)Haloalkyl, Halogen, Cyano und Nitro; (C6-C20)Heteroaryl; und (C6-C20)Heteroaryl substituiert mit einem oder mehreren Radikalen unabhängig ausgewählt aus (C1-C20)Alkyl, (C1-C6)Alkyl-O-, (C1-C6)Haloalkyl, Halogen, Cyano und Nitro ist;
    R2 und R2' Monoradikale sind, wobei jedes unabhängig aus der Gruppe bestehend aus Wasserstoff, (C1-C20)Alkyl, (C1-C6)Alkyl-O-, (C1-C6)Haloalkyl, Halogen, Cyano und Nitro ausgewählt wird; und
    Z1 bis Z4 Diradikale der Formel (III) sind
    Figure imgb0068
    in welcher A1 und A2 unabhängig aus der Gruppe bestehend aus -O- und -NR3- ausgewählt werden, wobei R3 aus der Gruppe bestehend aus Wasserstoff und (C1-C20)Alkyl ausgewählt wird; und
    G ein Diradikal ausgewählt aus der Gruppe bestehend aus -NH2, -P(=S)(R5), -S(=O)2-, (C1-C6)Alkyl, -S(=O)-, -C(=O)-, -P(=O)(R4)-, -P(=O)(NR6R7)- und -P(=O)(OR4) ist;
    R4 und R5 Monoradikale unabhängig ausgewählt aus der Gruppe bestehend aus (C1-C20)Alkyl; (C3-C8)Cycloalkyl; (C2-C20)Alkenyl; (C3-C20)Cycloalkyl; (C1-C20)Haloalkyl; (C1-C20)Alkyl-O-; (C6-C20)Aryl; (C6-C20)Heteroaryl; (C6-C20)Aryl substituiert mit einem oder mehreren Radikalen unabhängig ausgewählt aus (C1-C20)Alkyl, (C1-C6)Haloalkyl, (C1-C6)Alkyl-O-, Halogen, Cyano, Nitro; und (C6-C20)Heteroaryl substituiert mit einem oder mehreren Radikalen unabhängig ausgewählt aus (C1-C20)Alkyl, (C1-C6)Alkyl-O-, (C1-C6)Haloalkyl, Halogen, Cyano und Nitro sind;
    Y1 bis Y4 Triradikale sind, wobei jedes unabhängig aus der Gruppe bestehend aus (C1-C8)Alkyl; (C3-C7)Cycloalkyl; (C6-C20)Aryl; (C6-C20)Aryl substituiert mit einem oder mehreren Radikalen unabhängig ausgewählt aus der Gruppe bestehend aus: (C1-C20)Alkyl, (C1-C6)Alkyl-O-, (C1-C6)Haloalkyl, Halogen, Cyano und Nitro; (C6-C20)Heteroaryl; und (C6-C20)Heteroaryl substituiert mit einem oder mehreren Radikalen unabhängig ausgewählt aus der Gruppe bestehend aus: (C1-C20)Alkyl, (C1-C6)Alkyl-O-, (C1-C6)Haloalkyl, Halogen, Cyano und Nitro ausgewählt wird;
    R6 und R7 Monoradikale unabhängig ausgewählt aus der Gruppe bestehend aus -H und (C1-C20)Alkyl sind;
    FG1 und FG2 Monoradikale unabhängig ausgewählt aus der Gruppe bestehend aus H, OH und NHR8 sind, wobei R8 ein Radikal ausgewählt aus der Gruppe bestehend aus Wasserstoff und (C1-C20)Alkyl ist;
    wobei:
    (C6-C20)Aryl ein Ringsystem aus 6 bis 20 Kohlenstoffatomen darstellt, wobei das System von 1 bis 3 Ringe umfasst, wobei jeder der Ringe, welche das Ringsystem bilden: gesättigt, teilweise ungesättigt oder aromatisch ist; und isoliert, teilweise kondensiert oder völlig kondensiert ist;
    (C6-C20)Heteroaryl ein C-Radikal eines Ringsystems aus 6 bis 20 Elementen darstellt, wobei das System von 1 bis 3 Ringe umfasst, wobei mindestens einer der Ringe von eins bis vier Heteroatome unabhängig ausgewählt aus O, S und N enthält, und wobei jeder der Ringe, welche das Ringsystem bilden: gesättigt, teilweise ungesättigt oder aromatisch ist; und isoliert, teilweise kondensiert oder völlig kondensiert ist; und
    (C3-C20)Cycloalkyl sich auf einen gesättigten carbocyclischen Ring enthaltend von 3 bis 7 Kohlenstoffatome bezieht;
    sofern die Verbindung der Formel (Ib) anders als eine Verbindung der Formel (IV) oder (V) oder Stereoisomere derselben ist, und sofern die Verbindung der Formel (Ic) anders als eine Verbindung der Formel (VI) ist
    Figure imgb0069
    Figure imgb0070
    Figure imgb0071
    in welchen R9 C12H23 ist.
  2. Verbindung nach Anspruch 1, in welcher
    R1 ein Monoradikal ausgewählt aus der Gruppe bestehend aus Wasserstoff; (C1-C20)Alkyl; (C3-C20)Alkenyl; (C3-C20)Alkinyl; (C1-C6)Alkyl-O-; (C1-C20)Haloalkyl; (C6-C20)Aryl; (C6-C20)Aryl substituiert mit einem oder mehreren Radikalen unabhängig ausgewählt aus (C1-C20)Alkyl, (C1-C6)Alkyl-O-, (C1-C6)Haloalkyl, Halogen, Cyano und Nitro; (C6-C20)Heteroaryl; und (C6-C20)Heteroaryl substituiert mit einem oder mehreren Radikalen unabhängig ausgewählt aus (C1-C20)Alkyl, (C1-C6)Alkyl-O-, (C1-C6)Haloalkyl, Halogen, Cyano und Nitro ist;
    R2 und R2' Monoradikale sind, wobei jedes unabhängig aus der Gruppe bestehend aus Wasserstoff, (C1-C20)Alkyl, (C1-C6)Alkyl-O-, (C1-C6)Haloalkyl, Halogen, Cyano und Nitro ausgewählt wird; und
    G ein Diradikal ausgewählt aus der Gruppe bestehend aus -NH2, -S(=O)2-, (C1-C6)Alkyl, -S(=O)-, -C(=O)-, -P(=O)(R4)-, -P(=O)(NR6R7)- und -P(=O)(OR4)- ist, wobei R4 wie in Anspruch 1 definiert ist.
  3. Verbindung nach einem der Ansprüche 1-2, in welcher G ein Diradikal ausgewählt aus der Gruppe bestehend aus -S(=O)2-, (C1-C6)Alkyl, -S(=O)-, -C(=O)-, -P(=O)(R4)-, -P(=O)(NR6R7)- und -P(=O)(OR4)- ist, wobei R4 wie in Anspruch 1 definiert ist.
  4. Verbindung nach einem der vorhergehenden Ansprüche, in welcher Y1 bis Y4 C6-C20-Aryl sind.
  5. Verbindung nach einem der vorhergehenden Ansprüche, in welcher die Z1- bis Z4-Radikale Diradikale der Formel (III) wie in Anspruch 1 definiert sind, in welcher A1 und A2 gleich sind und -O-Diradikale darstellen.
  6. Verbindung nach Anspruch 5, in welcher Z1 bis Z4 unabhängig aus der Gruppe bestehend aus: -O-P(=O)(Ph)-O-, -O-P(=S)(Ph)-O-, -O-CH2-O-, -O-S(=O)2-O- und -O-P(=O)(NH2)-O- ausgewählt werden.
  7. Verbindung nach einem der Ansprüche 5 bis 6, in welcher Z1 bis Z4 unabhängig aus der Gruppe bestehend aus: -O-P(=O)(Ph)-O-, -O-CH2-O-, -O-S(=O)2-O- und -O-P(=O)(NH2)-O- ausgewählt werden.
  8. Verbindung nach einem der vorhergehenden Ansprüche, welche aus der Gruppe bestehend aus:
    Figure imgb0072
    Figure imgb0073
    Figure imgb0074
    Figure imgb0075
    Figure imgb0076
    Figure imgb0077
    Figure imgb0078
    Figure imgb0079
    Figure imgb0080
    Figure imgb0081
     und einem Stereoisomer derselben ausgewählt wird; wobei in der Verbindung der Formel (Ia6) und (Ib6): X O oder S bedeutet; und Ar Tolyl, Mesitylenyl, Naphthyl, Biphenylyl, Quinolinyl-N-oxid, Quinolinyl-N-sulfid und Anthracenyl bedeutet, vorzugsweise Ar Mesitylen, Naphthalen und Anthracen bedeutet.
  9. Verbindung nach Anspruch 8, welche aus der Gruppe bestehend aus:
    Figure imgb0082
    Figure imgb0083
    Figure imgb0084
    Figure imgb0085
    Figure imgb0086
    Figure imgb0087
    Figure imgb0088
    Figure imgb0089
     und einem Stereoisomer derselben ausgewählt wird; wobei in der Verbindung der Formel (Ia6) und (Ib6): R ein (C1-C6)Alkyl bedeutet; X O oder S bedeutet; und Ar Mesitylen, Naphthalen und Anthracen bedeutet.
  10. Verbindung nach Anspruch 8, welche aus der Gruppe bestehend aus den Verbindungen der Formel: (la1), (Ib1), (Ib11), (Ib12), (Ib13), (Ic3), (Ic4), und einem Stereoisomer derselben ausgewählt wird.
  11. In-vitro-Verwendung als Kreatinin-selektive Elektrode einer Membran umfassend:
    (i) eine Verbindung der Formel (la), (Ib) oder (Ic) oder ein Stereoisomer derselben wie in einem der Ansprüche 1 bis 10 definiert oder eine Verbindung der Formel (IV), (V) oder ein Stereoisomer derselben oder eine Verbindung der Formel (VI), wie in Anspruch 1 definiert, und
    (ii) eine Polymermatrix;
    (iii) einen Weichmacher; und
    (iv) ein Kationenaustauschersalz.
  12. In-vitro-Verwendung als Kreatinin-selektive Elektrode einer Elektrode umfassend die Membran nach Anspruch 11.
  13. In-vitro-Verwendung als Kreatinin-selektive Elektrode einer Vorrichtung umfassend die Elektrode nach Anspruch 12.
  14. Verfahren zur Quantifizierung von Kreatinin in einer Testprobe umfassend die folgenden Schritte: (a) das Inkontaktbringen der Testprobe jeweils mit einer Elektrode oder Vorrichtung, wie jeweils in Ansprüchen 12 und 13 definiert wird; und (b) das Korrelieren des Potenzialwertes mit der in der Probe enthaltenen Kreatininmenge.
  15. Verbindung zur In-vitro-Verwendung als Kreatinin-selektive Elektrode in der Diagnostik, ausgewählt aus der Gruppe bestehend aus den Verbindungen der Formel (la), (Ib) oder (Ic) wie in einem der Ansprüche 1 - 10 definiert, einer Verbindung der Formel (IV), einer Verbindung der Formel (V) oder einem Stereoisomer derselben, oder einer Verbindung der Formel (VI) wie in Anspruch 1 definiert.
EP15750267.5A 2015-01-19 2015-07-28 Calixpyrrolverbindungen und kreatininselektive elektroden damit Active EP3247709B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382007 2015-01-19
PCT/EP2015/067241 WO2016116175A1 (en) 2015-01-19 2015-07-28 Calixpyrrole compounds and creatinine-selective electrodes comprising them

Publications (3)

Publication Number Publication Date
EP3247709A1 EP3247709A1 (de) 2017-11-29
EP3247709B1 true EP3247709B1 (de) 2023-06-07
EP3247709C0 EP3247709C0 (de) 2023-06-07

Family

ID=52450033

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15750267.5A Active EP3247709B1 (de) 2015-01-19 2015-07-28 Calixpyrrolverbindungen und kreatininselektive elektroden damit

Country Status (4)

Country Link
US (1) US10591493B2 (de)
EP (1) EP3247709B1 (de)
ES (1) ES2951195T3 (de)
WO (1) WO2016116175A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3388825A1 (de) * 2017-04-12 2018-10-17 Medizinische Universität Innsbruck Potentiometrischer sensor zur quantitativen bestimmung von natriumkonzentration und kreatininkonzentration
EP3640633A1 (de) 2018-10-16 2020-04-22 UriSalt GmbH Mittel zur quantitativen bestimmung der kationischen elektrolytkonzentration und der kreatininkonzentration sowie deren verhältnissen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041819B2 (en) * 1996-04-05 2006-05-09 Board Of Regents, The University Of Texas System Halogenated calixpyrroles and uses thereof

Also Published As

Publication number Publication date
US20170370948A1 (en) 2017-12-28
ES2951195T3 (es) 2023-10-18
WO2016116175A1 (en) 2016-07-28
US10591493B2 (en) 2020-03-17
EP3247709C0 (de) 2023-06-07
EP3247709A1 (de) 2017-11-29

Similar Documents

Publication Publication Date Title
EP0097960B1 (de) Bis-Kronetherderivate und ihre Verwendung
Cuartero et al. Why ammonium detection is particularly challenging but insightful with ionophore-based potentiometric sensors–an overview of the progress in the last 20 years
CN109735328B (zh) 一种检测细胞内硫化氢的荧光探针及其制备方法和应用
CA2719255C (en) Biosensor with improved analyte specificity
CN108474758A (zh) 用于改进血液中的尿素检测的混合离子载体离子选择性电极
EP3247709B1 (de) Calixpyrrolverbindungen und kreatininselektive elektroden damit
Faridbod et al. Verapamil potentiometric membrane sensor for verapamil pharmaceutical analysis. Computational investigation
CN109142490A (zh) 全固态钠离子选择性传感器及其制备和应用
Kim et al. Functional polyterthiophene-appended uranyl-salophen complex: Electropolymerization and ion-selective response for monohydrogen phosphate
Hartman et al. Chloride-selective liquid-membrane electrodes based on lipophilic methyl-tri-N-alkyl-ammonium compounds and their applicability to blood serum measurements
JPH0215079A (ja) リチウムイオン選択組成物、電極および使用方法
US6635683B1 (en) Film responsive to bicarbonate ion
CN107290415B (zh) 电化学传感器及其试剂组合物和应用
Topcu et al. Ag+-selective poly (vinyl chloride) Membrane Electrode Based on [N, N'-ethylenebis-(3-methoxy salicylaldimine)]
EP0576548A1 (de) Magnesiumelektrode
Lewenstam Clinical analysis of blood gases and electrolytes by ion-selective sensors
JP2017520773A (ja) ナフトキノン系メディエーター及びｆａｄ−ｇｄｈを含有した酵素試薬層を有する、電気化学式分析検査ストリップ
CN112194641A (zh) 一种同时检测次氯酸和抗坏血酸的柔性电极及其制备方法和应用
Szymanska et al. Polymeric liquid membrane electrodes incorporated with macrocyclic hexaamines for screening adenine nucleotides
Vazifekhoran et al. Chromium measurement in pharmaceutical samples: a comparative study of three new membrane electrodes with different electron-ion exchangers
JP3659756B2 (ja) ナトリウムイオン選択性電極用イオノフォア
KR100257373B1 (ko) 티아졸 고리를 포함하는 벤조 크라운 에테르 유도체,그의 제조방법 및 용도
EP0458402B1 (de) Ionophore Hemispheranden mit verbesserten lipophilen Eigenschaften
JPH0961396A (ja) 陰イオン選択性電極
JP2005538926A (ja) アンモニウムイオノフォア

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170807

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20191001

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220110

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: UNIVERSITAT ROVIRA I VIRGILI

Owner name: INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS

Owner name: FUNDACIO INSTITUT CATALA D'INVESTIGACIO QUIMICA

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: UNIVERSITAT ROVIRA I VIRGILI

Owner name: INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS

Owner name: FUNDACIO INSTITUT CATALA D'INVESTIGACIO QUIMICA

INTG Intention to grant announced

Effective date: 20220627

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1574735

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230615

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015083889

Country of ref document: DE

U01 Request for unitary effect filed

Effective date: 20230705

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI

Effective date: 20230717

U20 Renewal fee paid [unitary effect]

Year of fee payment: 9

Effective date: 20230717

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2951195

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20231018

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230907

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230714

Year of fee payment: 9

Ref country code: ES

Payment date: 20230801

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230908

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231007

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015083889

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230731

26N No opposition filed

Effective date: 20240308